Gsa Capital Partners LLP Ascendis Pharma A/S Transaction History

Gsa Capital Partners LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 03, 2024	BUY	$123.45 - $159.4 $810,325 - $1.05 Million	6,564 New	6,564 $992,000
Q1 2022 May 11, 2022	SELL	$102.18 - $135.75 $835,321 - $1.11 Million	-8,175 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$127.1 - $169.66 $1.04 Million - $1.39 Million	8,175 New	8,175 $1.1 Million
Q4 2020 Feb 03, 2021	SELL	$151.2 - $182.76 $404,611 - $489,065	-2,676 Closed	0 $0
Q3 2020 Nov 06, 2020	BUY	$134.29 - $154.32 $359,360 - $412,960	2,676 New	2,676 $413,000
Q1 2020 May 12, 2020	SELL	$97.01 - $145.11 $210,899 - $315,469	-2,174 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$91.45 - $139.12 $198,812 - $302,446	2,174 New	2,174 $302,000

244

58.8M

250K

377K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.61B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.